H. pylori Eradication and Hypercholesterolemia Management

Primary Recommendations

The American College of Gastroenterology recommends bismuth quadruple therapy for 10-14 days as first-line treatment for H. pylori eradication, consisting of bismuth subsalicylate, tetracycline 500 mg four times daily, metronidazole 500 mg four times daily, and PPI twice daily, for patients with elevated LDL cholesterol of 3.7 mmol/L 1
The American Heart Association recommends initiating atorvastatin 10-20 mg once daily after completing H. pylori eradication therapy to achieve a target LDL-C of <3.0 mmol/L [@11@]

Bismuth quadruple therapy is preferred in areas of high clarithromycin resistance and provides superior eradication rates without requiring susceptibility testing, with a duration of 10-14 days [2, @6@, 3]
The urea breath test (UBT) should be performed at minimum 4 weeks after completing therapy to confirm eradication, with a sensitivity of 94.7-97% and specificity of 95-100% [@10@]

Atorvastatin 10-20 mg once daily is recommended to achieve a target LDL-C of <3.0 mmol/L, with an expected LDL-C reduction of approximately 39% and total cholesterol reduction of approximately 31% [@11@]
The American College of Cardiology recommends waiting until H. pylori eradication is complete before starting statin therapy to avoid potential gastric irritation during active infection treatment [@13@]

The urea breath test (UBT) should be performed at minimum 4 weeks after completing therapy to confirm eradication, with a sensitivity of 94.7-97% and specificity of 95-100% [@10@]
A follow-up lipid panel should be performed at 4-6 weeks to assess response to statin therapy [@11@]
The patient should be referred to general surgery for elective repair evaluation of the umbilical hernia after H. pylori eradication is confirmed and the patient is stable on statin therapy 2